Dendritic Cells in XXXX : The Currently Available Information and Possibilities to use Dendritic Cells for Immunotherapeutic Approaches.

@entity355 @entity5 @entity5072 @entity344 @entity420
UNASSIGNED: @entity420 ( @entity420 ) is the second frequent @entity5 . @entity355 ( @entity355 ) takes precedence over @entity420 . @entity355 is a metaplastic change of the stratified squamous epithelium to the intestinal columnar epithelium due to the @entity344 . Further, the disease takes the @entity5072 stage followed by @entity420 . An initial immune response is an essential reaction of a body to an occurrence of alien/modified cells to be removed. It has been appreciated that an inflammatory reaction occurs in the early stages of @entity420 or even in @entity355 . Dendritic cells (DCs) play a key role in a frontier of an immune response due to their advanced ability to recognize foreign antigens and mobilize naive T cells to effectors. However, in a @entity5 , @entity5 -delivered immunosuppression occurs in a variety of mechanisms that alter/switch the functionality of DCs from immune activating to immune suppressive cells. In this brief review, we consider @entity5 -induced paths of a capacity of @entity5 cells to down-regulate DCs, with a focus on @entity420 , and also discuss a possibility to use DCs for immunotherapeutic approaches. Indeed, DCs represent a promising tool for developing new immunotherapeutic approaches for @entity5 treatment including @entity420 . It has been reported to achieve effective DC-mediated immune responses by raising anti- @entity5 cytotoxic T cell responses against @entity5 antigens through loading DCs with total @entity5 RNA. However, more studies should be performed in order to understand a precise role in @entity5 -induced mechanisms of DC suppression in @entity355 / @entity420 . Likely, these mechanisms should involve general carcinogenic and @entity420 -specific pathways.
